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Abstract
Aquaporins (AQPs) are water channel molecules that allow the passage of water through the lipid bilayers of cell
membranes. AQP1, AQP4 and AQP9 are expressed in the central nervous system and AQP4 is well known as the target
of auto-antibodies in Devic’s neuromyelitis optica. The role of AQPs in facilitating water movements suggests a link with
oedema formation and resolution in the brain. Furthermore, AQPs are also involved in process formation in glial cells with
a close link to neuroinflammation. This mini-review gives an overview of what is currently known about the role of AQPs
in different neurological disorders.
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Introduction
Aquaporins came to the attention of neurologists mainly
due to Devic’s syndrome, an autoimmune condition
associated with anti-AQP4 antibodies found in serum.
Aquaporins, as indicated by their name, are water chan-
nel molecules that allow water to cross the hydrophobic
lipid bilayers of cellular membranes. AQPs were first
described by Peter Agre, an American physician and
molecular biologist, while studying red blood cell mem-
branes and the Rhesus group. He discovered a red cell
membrane protein, CHIP28, with homologies to proteins
expressed in various tissues such as renal tubules, fruit
fly brains and plant roots.1 He went on to show this
protein was a water channel, now termed Aquaporin-1
(AQP1), providing an explanation for the rapid water
movement through hydrophobic red cell membranes.2
This led to the discovery of the AQP family of water
channel proteins. Peter Agre was awarded the Nobel
Prize in Chemistry in 2003, which he shared with
Roderick MacKinnon, for their ‘discoveries concerning
structure and function of channels in cell membranes’.
The finding that AQPs were expressed in the brain
prompted research into possible links between AQPs and
neurological conditions associated with disturbed water
movements such as cerebral oedema, with the hope of
using AQPs as therapeutic targets to modulate cerebral
water exchange.
Aquaporins
AQPs are proteins of approximately 30kD located in cell
membranes. They contain six transmembrane domains, two
intracellular loops and three extracellular loops that form a
channel that allows passive water movement following
osmotic or oncotic gradients between the extra- and intra-
cellular spaces. The AQP family shares a common consen-
sus motif, asparagine-proline-alanine (NPA), which
contributes to the specificity of the pore. Most AQPs form
tetramers, although each AQP molecule constitutes an indi-
vidual channel by itself. Twelve AQPs have been identified
so far. The majority are permeable to only water but some
are also permeable to small solutes such as glycerol or
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lactate (aquaglyceroporins). Currently three main AQPs
have been observed and studied in the brain: AQP1, AQP4
and AQP9.
AQP1, permeable to only water, has been observed in
epithelial cells of the choroid plexus at the site of produc-
tion of the cerebrospinal fluid (CSF). Interestingly,
although endothelial cells commonly express AQP1, cere-
bral endothelial cells do not and it appears that astrocytes
are responsible for the downregulation of AQP1 in the
central nervous system (CNS). In cultures of brain
endothelial cells, cells regain the expression AQP1 pro-
gressively after a few passages and this expression is
downregulated in co-cultures of brain endothelial cells
with astrocytes.3 This indicates that an interaction
between elements of the neurovascular unit contributes
to the phenotype of endothelial cells in the blood–brain
barrier (BBB).3 AQP1 was also observed in primary sen-
sory neurons, such as those in the dorsal root ganglion,
and is proposed to be involved in pain perception.4,5
AQP4, another water-only channel, is the most abundant
AQP in the brain. It is expressed mostly in astrocytes and
ependymal cells. In astrocytes, AQP4 localizes in the end
feet in contact with microvessels and synapses (Figure 1).
Astrocyte processes and their end feet surround the brain
microvessels and also constitute the glia limitans, a glial
layer at the outer boundary of the CNS. The strategic loca-
tion of AQP4 on astrocytic end feet covering the micro-
vasculature positions it at the site of water exchange in the
BBB. On the other hand, astrocyte end feet of the glia
limitans bordering the outer surface of the brain are in
contact with the pia mater and in the vicinity of the CSF
in the subarachnoid space (Figure 1). Therefore, expression
of AQP4 in both ependymal cells lining the ventricles and
astrocytes of the glia limitans places it at the interface of the
CSF and brain parenchyma, at the sites of water movement
between the CSF and the brain. Recently, AQP4 found on
astrocyte end feet, which are in contact with cerebral blood
vessels, has been linked with CSF and solute movements in
the perivascular space6 and to the clearance of metabolites
from the brain tissue such as ß-amyloid.7 It has been pro-
posed that CSF enters the perivascular space of brain tissue
around penetrating arterioles and exchanges with inster-
stitial fluid. Insterstitial fluid and solutes leave the brain in
the perivascular spaces of venules and veins. This phe-
nomenon is facilitated by astroglial water movements
through AQP4.6 By analogy to the lymphatic system
Figure 1. The most abundant AQP expressed in the brain (in astrocytes) is AQP4 (purple). AQP4 is expressed mainly on astrocytic
endfeet. Astrocytes extend their endfeet to the glia limitans (top) where AQP4 is involved in water movements between the CSF and
the brain, to capillaries (left), where it plays a role in water movements in oedema formation and resolution and to synapses (center),
where it is involved in synapse homeostasis. AQP9 (blue) in the brain is expressed in the cytoplasmic membrane and mitochondria (not
illustrated) of astrocytes. Both AQP4 and 9 play a role in water movements involved in process formation and elongation (right).
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found outside the brain, the perivascular space system was
named the glymphatic system. Recently, the glymphatic
system was proposed to contribute to lactate concentration
changes in the brain, in correlation with sleep–wake
cycles and sleep homeostasis.8 AQP4 is also associated
with cell movement, the size of the extracellular space and
connectivity between neurons.
AQP9 is an aquaglyceroporin that is permeable to both
water and small solutes such as glycerol, monocarboxylate
and urea. It is present as two isoforms of 30 and 26 kD. The
30 kD isoform is expressed in the cytoplasmic membrane
and on the 26 kD isoform on the inner mitochondrial
membrane. AQP9 was shown to play an important role
in cell morphology in leucocytes, allowing the outgrowth
of processes,9 while the presence of AQP9 in the liver is
associated with energy balance.10 In the brain, AQP9 is
preferentially expressed in catecholaminergic neurons,
for example, in tanycytes of the medio-basal hypo-
thalamus.11,12 It is also expressed in astrocytes (Figure 1)
and our groups have shown that AQP9 expression is
induced in astrocytes13 after cerebral ischemia. However,
currently the expression of AQP9 in the CNS is debated as
other authors have described expression in hepatocytes,
epididymis, vas deferens and epidermis but not in
brain.14,15 Discrepancies between observations have been
attributed to differences between species, different splice
variants or antibody specificity.14 Also, AQP9 mRNA has
been detected in the brains of both rodents and non-human
primates, arguing in favour of AQP9 expression in the
CNS.11,16 To date, the role of AQP9 in brain is thought
to be associated with brain energy metabolism17 and astro-
gliosis after stroke.18
Involvement of AQPs in specific
neurological disorders
Role of AQPs in oedema formation and resolution
After the description of the location and expression of
AQP4 in the brain,19 various studies focused on its poten-
tial role in the oedema process. The field benefited from
the generation of AQP4 knockout (AQP4/) mice by
Verkman and colleagues, who showed the importance of
AQP4 in early oedema formation after water intoxication
and in experimental stroke.20 So far, the available data
strongly suggest that AQP4 promotes the formation of
cytotoxic oedema by facilitating the entry of water into
astrocytes. However, the absence of AQP4 decreases the
water clearance after infusion of saline solution into the
brain parenchyma leading to a significantly higher
increase in intracranial pressure.21 So far, most immuno-
histological studies showed that changes in AQP4 expres-
sion seem to parallel changes in the oedema process (for a
detailed review, see Badaut et al.22). However, the pattern
of AQP4 expression changes differs between brain disor-
ders. Most of the work on AQP4 and oedema has been
carried out in stroke models and we discuss this in more
detail below.
Devic’s disease
Neuromyelitis optica (NMO) or Devic’s disease is an auto-
immune demyelinating disease of the CNS affecting mostly
the optic nerve and spinal cord (for a detailed review, see
Yang et al.23). It is rare in the European population
(1:100,000/year) but more frequent inWest Indian and Asian
populations where it represents up to 50% of demyelinating
CNS disorders. A significant number of Devic’s patients,
although not all, have antibodies against AQP4 (AQP4-Ab
or NMO-IgG). Initially questioned, the pathogenic role of
AQP4-Ab is becoming increasingly clear as it has been shown
inmice that intracerebral injection ofAQP4-Ab isolated from
NMOpatients, co-injected with human complement, leads to
inflammation and demyelination reproducing the features of
NMO.24,25 AQP4-Ab appear to contribute to the disturbance
in the immunoregulatory function and barrier capacity of
astrocytes. The term astrocytopathywas proposed to charac-
terize this disease.26 Several questions however remain unan-
swered about the AQP involvement: AQP4 is expressed in
astrocytes throughout the CNS and so the preferential invol-
vement of the optic nerve and spinal cord is not clear, neither
the fact that many other organs express AQP4, including the
kidney, and are not affected.
Cerebral ischemia/stroke
Ischemic stroke can be a devastating disease and has high
incidence, leaving many patients with a handicap. Cerebral
oedema is an important aspect of ischemia-induced cerebral
tissue alterations. The cytotoxic oedema, demonstrated by a
reduced apparent diffusion coefficient (ADC) in the early
hours after an ischemic insult, is a hallmark of ischemic stroke
in magnetic resonance imaging. A second later phase of
oedema, termed vasogenic oedema, reaches a peak between
24 h and 72 h after ischemic stroke onset. The swelling of
ischemic brain tissue can cause compression and damage of
other structures such as the brain stem, with further neurolo-
gical worsening or even death. This phenomenon, termed
mass effect, is a feared complication of ischemic stroke. Pos-
sible roles of AQP4 in stroke outcome have been investigated
in AQP4-deficient mice. Mice lacking AQP4 develop less
pronounced cerebral oedema after stroke in a mouse model
of severe permanent cerebral ischemia.20Amore recent study
from our labs, using the milder transient cerebral ischemia
stroke model in AQP4 knockout mice, showed decreased
mortality and increased motor recovery up to 14 days after
stroke. In this model, behavioural improvement was asso-
ciatedwith a smaller lesion volume and decreased neuronal
cell death and neuroinflammation, without a direct effect
on oedema formation.27 In wild-type (WT) mice, we
observed an early increase (1 h after ischemia onset) in
AQP4 expression on astrocytic end feet lining the
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capillaries of the lesion border, coinciding with an early
phase of hemispheric swelling.28 Using a preconditioning
paradigm of intracerebroventricular thrombin injection 24
h before ischemia to trigger endogenous neuroprotection
mechanisms,29,30 we demonstrated increased tolerance to
ischemia and reduced hemispheric swelling coinciding
with a further enhancement of perivascular AQP4 expres-
sion at 1 h after ischemia.29,31 This observation suggests
that the early AQP4 upregulation on astrocytic end feet
lining capillaries is part of an endogenous protective
mechanism to attenuate cerebral oedema. These different
observations in distinct models illustrate the particular
functions of astrocytes as part of the BBB and in regulation
of inflammatory processes.
AQP9 expression is induced in astrocytes after cerebral
ischemia around the lesion, but also at a distance from the
ischemia in the cell bodies and on processes, but not on
perivascular end feet.13 Using the thrombin preconditioning
paradigm, we observed that thrombin addition before stroke
further enhanced the AQP9 expression observed in stroke
with associated morphological changes suggesting AQP9
expression may have a role in astrocyte activation and the
astroglial response to ischemic brain injury. Importantly in
this respect, we recently showed that AQP9 overexpression
influences astrocyte morphology in cultures of astrocytes,
with an increase in cellular process complexity,18 as was
shown earlier in leucocytes. Another hypothesis for
increased expression of AQP9 after stroke is that AQP9
could facilitate clearance of the accumulated lactate and
glycerol from the extracellular space following the stroke.18
Glioblastoma
Expression of AQP1 and AQP4 is also reported in human
samples from glial cell tumours.32,33 The role of AQPs is at
present unclear in malignant glial cells. An increase in
AQP9 mRNA and protein expression was measured in
human astrocytic tumours, reaching higher values in
high-grade tumours compared to normal brain tissue.34,35
As AQPs are involved in filopodia formation by facilitating
water entry into the cell process, it has been proposed that
the presence of AQPs on tumour cells could be linked to
cell migration and invasion of the surrounding nervous
tissue by tumour cells. Furthermore, the presence of AQP1
promotes tumour metastasis.25,36
Traumatic brain injury
In traumatic brain injury (TBI), AQP4 plays a role in astro-
gliosis after the injury. Adult AQP4/ mice developed a
stronger microglial reaction and attenuated astrogliosis
compared to WT mice subjected to TBI. One month after
injury, the AQP4/ mice were more vulnerable to epi-
leptic seizures than WT mice.37 Similar results were
obtained when juvenile mice were subjected to TBI
(jTBI).38 AQP4 knock-down using siRNA resulted in
attenuated astrogliosis and enhanced microglial activation
3 days post-injury in jTBI. This suggests that the astroglial
reaction plays a key role in regulating microglia and under-
scores the role of AQP4 in neuroinflammation (for a
detailed review, see Badaut et al.22).
Hydrocephalus
Hydrocephalus presents as dilated ventricles. While
obstructive hydrocephalus is due to a compression of the
CSF flow path, for example, at the level of the aqueduct of
Sylvius, communicating hydrocephalus results from an
imbalance in CSF production and elimination. AQP1 and
AQP4 are expressed at critical locations for CSF produc-
tion and drainage. Interestingly, the expression of AQP4 in
brain samples from patients suffering from hydrocephalus
is increased and less polarized to astrocytic end feet than in
controls.39 The role of AQP1 and AQP4 in hydrocephalus
pathogenesis has been investigated using mutant mice.
AQP1 is expressed on the epithelium of the choroid plexus
at the site of CSF production. In AQP1/ mice, the intra-
cranial pressure is lower than in WT mice and the produc-
tion of CSF is reduced by 25%. A mouse hydrocephalus
model induced by Kaolin injection into the cisterna magna
that leads to an obstruction of the outflow from the fourth
ventricle was tested in AQP4/ mice: Mutant mice had a
higher intracranial pressure and more dilated ventricles
than WT mice.40 This can be explained by a reduced drai-
nage of CSF in the absence of AQP4.
Epilepsy
Astrocytes express AQPs and extend their processes to both
capillaries and synapses. They play an important role in
neuronal metabolism and modulation of neuronal excitabil-
ity and synaptic transmission. In mice deficient in AQP4,
the threshold for seizures is reduced while the seizure dura-
tion is extended, showing a link between AQPs and epi-
lepsy (for a detailed review, see Binder et al.41). The
underlying mechanism may be an impairment of Kþ home-
ostasis in the absence of AQP4.42 Furthermore, in hippo-
campal atrophy, a feature of mesio-temporal lobe epilepsy,
AQP4 expression is increased in samples from atrophic
hippocampi from epileptic patients.43
Neurodegenerative diseases
Presence in blood of antibodies against AQP4 has been
identified as a potential biomarker in Devic’s disease as
discussed above. The role of the AQPs in multiple sclero-
sis (MS) has not been studied extensively so far. In a
model of MS, experimental autoimmune encephalomye-
litis (EAE), an upregulation of AQP4 was observed in
correlation with BBB disruption characterized by a
decrease in tight junction proteins such as occludin.44
Accordingly, the absence of AQP4/ is associated with
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a less severe clinical deficit score and tissue inflammation
after EAE and lipopolysaccharide injection compared to
WT animals, suggesting a deleterious role of AQP4 in MS
pathophysiology.45 The benefits due to AQP4 absence
could be linked to a decreased production of the proin-
flammatory cytokines, tumour necrosis factor-alpha and
interleukin (IL)-6 as seen in AQP4/ compared to astro-
cyte cultures from WT mice.46
In Alzheimer’s disease (AD), the levels of AQP1 and
AQP4 are altered, with an increased number of AQP1
expressing astrocytes in the cortex in AD brains. Interest-
ingly, AQP1 expression was not high in the vicinity of
senile plaques.47 The level of expression of AQP1 differs
depending on the intensity of the A immunoreactivity,
with high expression of AQP1 in astrocytes close to low
A immunoreactivity and the absence of AQP1 in the
astrocytes adjacent to high A immunoreactivity. On the
other hand, AQP4 expression in astrocytes is increased in
association with A in patients in the vicinity of senile
plaques.47 The role of these changes is still debated. In
rodent models of AD, vascular alterations have been
observed with loss of AQP4 expression in astrocyte end
feet.48 Changes in AQP4 expression in astrocyte end feet
could affect the clearance of A from the perivascular
space.7 It is important to point out that the changes in AQP4
in rodent preclinical models do not seem to reproduce the
alterations observed in AD patients.
In inflammation, AQP4 has been related to the produc-
tion of cluster of differenciation (CD)4þ and CD25þ reg-
ulatory T cells.46 The absence of AQP4 possibly interrupts
the immunosuppressive regulators in Parkinson’s disease,
leading to increased microglial activation and a worse out-
come due to enhanced loss of dopaminergic neurons after
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administra-
tion.46 In summary, it is likely that AQPs contribute to
various pathophysiological mechanisms leading to
neurodegeneration.
Molecular mechanisms for AQPs
in mediating disease pathology
AQPs are water channels and their presence facilitates
water movements through cell membranes. Thereby, AQPs
influence oedema development and resolution as well as
volume and shape changes of cells. In particular, they are
involved in cell process formation such as is the case for
AQP9 in astrocytes involved in astrogliosis, which may be
both beneficial and deleterious. Astrocytic swelling
favoured by AQP4 was shown to lead to Caþþ signalling
via the release of ATP and activation of purinergic recep-
tors.49 Disturbed AQP4 expression could influence the
glymphatic system and clearance of potentially toxic
solutes such as A from the perivascular space.7
As indicated above, many of the brain disorders are
associated with a neuroinflammatory process, which
encompasses activation of astrocytes as well as secretion
of cytokines and chemokines. AQP4 is commonly upregu-
lated in neuroinflammation.38 Indeed, IL-1 is increased in
several brain disorders and has been shown to induce AQP4
expression in a concentration-dependent manner.50,51
Regarding the mechanism of action, IL-1 has been shown
to upregulate AQP4 at the transcriptional level: Down-
stream of the IL-1 receptor, NFKB is translocated to the
nucleus and binds the AQP4 gene promoter.50,52 Similarly,
the high mobility group box protein-1 (HMGB1) released
by necrotic neurons induces a neuroinflammatory response
together with an increase in AQP4 possibly triggered, at
least in part by the pro-inflammatory cytokine IL-6.53 This,
in turn, could lead to astrocyte volume changes and Caþþ
signalling.49 It is interesting to outline the bidirectional role
on cytokine regulation. Reduced production of the proin-
flammatory cytokines, tumour necrosis factor-alpha and
IL-6 was observed in AQP4/ compared to WT mice
astrocyte cultures, whereas, in these same cultures,
adenovirus-mediated increases in the expression of AQP4
or AQP1 lead to increased release of the same cytokines.46
Additionally, it has been shown that water transport
mediated by AQP1 induces IL-1 release from macro-
phages,54 although this phenomenon has not been studied
in the CNS.
Activation of the protein kinase C pathway in astrocyte
cultures induced a decrease in AQP4 and AQP9 mRNA and
protein.55 V1a receptor stimulation is known to induce acti-
vation of protein kinase C, and application of vasopressin on
cortical slices induced changes in water flux through the
astrocytic syncytium. In addition to protein kinase C, inhibi-
tion of one of the Mitogen activated protein kinases (MAP-
kinases), JNK, in a subarachnoid haemorrhage model has
been associated with increased AQP4 expression and
decreased oedema formation. In summary, the regulation
of AQP expression is tightly linked with neuroinflammatory
mechanisms with bidirectional flow: With, for example,
inflammatory signals promoting the expression of AQP4,
AQP4 facilitates astrocytic activation but seems to limit
microglial activation.
Conclusions
The study of AQPs in the brain reveals new and unexpected
roles for these channels in CNS cell physiology and phy-
siopathology (Figure 1). Apart from Devic’s disease, evi-
dence linking AQPs to the pathogenesis of specific
neurological disorders is weak. There are been multiple
reports and very heterogeneous findings and effects that
depend on the studied pathologies and models used. It
should be pointed out that the timing of observations after
injury is critical. AQPs are passive channels allowing the
flow of water (and in some cases small solutes) through
lipophilic membranes and the roles of such channels may
be diagonally opposed at different time points in develop-
ment and resolution of a neurological disorder. Impor-
tantly, there is still a lack of selective pharmacological
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compounds to study the effect of specific blockage of
AQPs to allow the analysis of their physiological and
pathological roles. Many studies are based on transgenic
mice, where developmental adjustments and redundancy
may mask the true role of the specific endogenous AQP.
Knock-down strategies, which have the advantage of indu-
cing an acute change in gene expression, are however pro-
viding assessment of AQP function. As water and solute
movements are part of lesion development and resolution
in many neurological disorders, a fine characterization and
better understanding of these phenomena could allow tar-
geted interventions to attenuate lesion progression and
enhance recovery after injury.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
Research grants from the Swiss Science Foundation (FNS
31003A_163465), the Biaggi Foundation and the Juchum Foun-
dation (LH); eraNET neuron CNSaflame, eraNET neuron
TRAINS and, ANR-TRAIL (JB).
References
1. Denker BM, Smith BL, Kuhajda FP, et al. Identification,
purification, and partial characterization of a novel Mr
28,000 integral membrane protein from erythrocytes and
renal tubules. J Biol Chem 1988; 263:15634–15642.
2. Smith BL and Agre P. Erythrocyte Mr 28,000 transmembrane
protein exists as a multisubunit oligomer similar to channel
proteins. J Biol Chem 1991; 266:6407–6415.
3. Dolman D, Drndarski S, Abbott NJ, et al. Induction of aqua-
porin 1 but not aquaporin 4 messenger RNA in rat primary
brain microvessel endothelial cells in culture. J Neurochem
2005; 93:825–833.
4. Zhang H and Verkman AS. Aquaporin-1 tunes pain percep-
tion by interaction with Na(v)1.8 Naþ channels in dorsal root
ganglion neurons. J Biol Chem 2010; 285: 5896–5906.
5. Borsani E. Aquaporins in sensory and pain transmission. Curr
Neuropharmacol 2010; 8: 122–127.
6. Iliff JJ and Nedergaard M. Is there a cerebral lymphatic sys-
tem? Stroke 2013; 44: S93–95.
7. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway
facilitates CSF flow through the brain parenchyma and the
clearance of interstitial solutes, including amyloid beta. Sci
Transl Med 2012; 4: 147ra111.
8. Lundgaard I, Lu ML, Yang E, et al. Glymphatic clearance
controls state-dependent changes in brain lactate concentra-
tion. J Cereb Blood Flow Metab 2016; 37(6): 2112–2124.
9. Loitto VM, Huang C, Sigal YJ, et al. Filopodia are induced by
aquaporin-9 expression. Exp Cell Res 2007; 313: 1295–1306.
10. Kuriyama H, Shimomura I, Kishida K, et al. Coordinated
regulation of fat-specific and liver-specific glycerol channels,
aquaporin adipose and aquaporin 9. Diabetes 2002; 51:
2915–2921.
11. Elkjaer M, Vajda Z, Nejsum LN, et al. Immunolocalization of
AQP9 in liver, epididymis, testis, spleen, and brain. Biochem
Biophy Res Commun 2000; 276: 1118–1128.
12. Badaut J, Petit JM, Brunet JF, et al. Distribution of aquaporin
9 in the adult rat brain: preferential expression in catechola-
minergic neurons and in glial cells. Neuroscience 2004; 128:
27–38.
13. Badaut J, Hirt L, Granziera C, et al. Astrocyte-specific
expression of aquaporin-9 in mouse brain is increased after
transient focal cerebral ischemia. J Cereb Blood Flow Metab
2001; 21: 477–482.
14. Rojek AM, Skowronski MT, Fuchtbauer EM, et al. Defective
glycerol metabolism in aquaporin 9 (AQP9) knockout mice.
Proc Natl Acad Sci U S A 2007; 104: 3609–3614.
15. Oklinski MK, Skowronski MT, Skowronska A, et al.
Aquaporins in the spinal cord. Int J Mol Sci 2016;
17(12): 2050.
16. Arcienega II, Brunet JF, Bloch J, et al. Cell locations for
AQP1, AQP4 and 9 in the non-human primate brain. Neu-
roscience 2010; 167: 1103–1114.
17. Badaut J, Brunet JF, Guerin C, et al. Alteration of glucose
metabolism in cultured astrocytes after AQP9-small interfer-
ence RNA application. Brain Res 2012; 1473: 19–24.
18. Hirt L, Price M, Mastour N, et al. Increase of aquaporin 9
expression in astrocytes participates in astrogliosis. J Neu-
rosci Res 2017; 96(2): 194–206.
19. Jung JS, Bhat RV, Preston GM, et al. Molecular character-
ization of an aquaporin cDNA from brain: candidate osmor-
eceptor and regulator of water balance. Proc Natl Acad Sci U
S A 1994; 91: 13052–13056.
20. Manley GT, Fujimura M,Ma T, et al. Aquaporin-4 deletion in
mice reduces brain edema after acute water intoxication and
ischemic stroke. Nat Med 2000; 6: 159–163.
21. Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4
facilitates reabsorption of excess fluid in vasogenic brain
edema. FASEB J 2004; 18: 1291–1293.
22. Badaut J, Fukuda AM, Jullienne A, et al. Aquaporin and brain
diseases. Biochim Biophys Acta 2014; 1840: 1554–1565.
23. Yang X, Ransom BR and Ma JF. The role of AQP4 in neu-
romyelitis optica: more answers, more questions. J Neuroim-
munol 2016; 298: 63–70.
24. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection
of neuromyelitis optica immunoglobulin G and human com-
plement produces neuromyelitis optica lesions in mice. Brain
2010; 133: 349–361.
25. Verkman AS. Aquaporins in clinical medicine. Annu Rev
Med 2012; 63: 303–316.
26. Sofroniew MV. Astrocyte barriers to neurotoxic inflamma-
tion. Nat Rev Neurosci 2015; 16: 249–263.
27. Hirt L, Fukuda AM, Ambadipudi K, et al. Improved long-term
outcomeafter transient cerebral ischemia in aquaporin-4knock-
out mice. J Cereb Blood Flow Metab 2016; 37(1): 277–290.
6 Clinical & Translational Neuroscience
28. Ribeiro MD, Badaut J, Price M, et al. Thrombin in ischemic
neuronal death. Exp Neurol 2006; 198: 199–203.
29. Granziera C, Thevenet J, Price M, et al. Thrombin precondi-
tioning improves functional outcome after focal cerebral
ischemia. Stroke 2006; 37: 683–684.
30. Price M, Badaut J, Thevenet J, et al. Activation of c-Jun in the
nuclei of neurons of the CA-1 in thrombin preconditioning
occurs via PAR-1. J Neurosci Res 2010; 88: 1338–1347.
31. Hirt L, Ternon B, Price M, et al. Protective role of early
aquaporin 4 induction against postischemic edema formation.
J Cereb Blood Flow Metab 2009; 29: 423–433.
32. Maugeri R, Schiera G, Di Liegro CM, et al. Aquaporins and
brain tumors. Int J Mol Sci 2016; 17: 1029.
33. Hayashi Y, Edwards NA, Proescholdt MA, et al. Regulation
and function of aquaporin-1 in glioma cells. Neoplasia 2007;
9: 777–787.
34. Warth A, Mittelbronn M, Hulper P, et al. Expression of the
water channel protein aquaporin-9 in malignant brain tumors.
Appl Immunohistochem Mol Morphol 2007; 15: 193–198.
35. Jelen S, Parm Ulhoi B, Larsen A, et al. Aqp9 expression in
glioblastoma multiforme tumors is limited to a small popu-
lation of astrocytic cells and cd15(þ)/calb(þ) leukocytes.
PloS One 2013; 8: e75764.
36. Hu J and Verkman AS. Increased migration and metastatic
potential of tumor cells expressing aquaporin water channels.
FASEB J 2006; 20: 1892–1894.
37. Lu DC, Zador Z, Yao J, et al. Aquaporin-4 reduces post-
traumatic seizure susceptibility by promoting astrocytic glial
scar formation in mice. J Neurotrauma 2011. doi: 10.1089/
neu.2011.2114
38. Fukuda AM, Adami A, Pop V, et al. Posttraumatic reduction
of edema with aquaporin-4 RNA interference improves acute
and chronic functional recovery. J Cereb Blood Flow Metab
2013; 33: 1621–1632.
39. Skjolding AD, Holst AV, Broholm H, et al. Differences in
distribution and regulation of astrocytic aquaporin-4 in
human and rat hydrocephalic brain. Neuropathol Appl Neu-
robiol 2013; 39: 179–191.
40. Bloch O, Auguste KI, Manley GT, et al. Accelerated progres-
sion of kaolin-induced hydrocephalus in aquaporin-4-
deficient mice. J Cereb Blood Flow Metab 2006; 26:
1527–1537.
41. Binder DK, Nagelhus EA and Ottersen OP. Aquaporin-4 and
epilepsy. Glia 2012; 60: 1203–1214.
42. Binder DK, Yao X, Zador Z, et al. Increased seizure duration
and slowed potassium kinetics in mice lacking aquaporin-4
water channels. Glia 2006; 53: 631–636.
43. Lee TS, Eid T, Mane S, et al. Aquaporin-4 is increased in the
sclerotic hippocampus in human temporal lobe epilepsy. Acta
Neuropathol 2004; 108: 493–502.
44. Vaknin-Dembinsky A, Abramsky O, Petrou P, et al. Myasthe-
nia gravis-associated neuromyelitis optica-like disease: an
immunological link between the central nervous system and
muscle? Archiv Neurol 2011; 68: 1557–1561.
45. Li L, Zhang H and Verkman AS. Greatly attenuated experi-
mental autoimmune encephalomyelitis in aquaporin-4 knock-
out mice. BMC Neurosci 2009; 10: 94.
46. Li L, Zhang H, Varrin-Doyer M, et al. Proinflammatory role
of aquaporin-4 in autoimmune neuroinflammation. FASEB J
2011; 25: 1556–1566.
47. Hoshi A, Yamamoto T, Shimizu K, et al. Characteristics of
aquaporin expression surrounding senile plaques and cerebral
amyloid angiopathy in Alzheimer disease. J Neuropathol Exp
Neurol 2012;71: 750–759.
48. Zago W, Schroeter S, Guido T, et al. Vascular alterations in
PDAPP mice after anti-A immunotherapy: implications for
amyloid-related imaging abnormalities. Alzheimer’s Dement
2013; 9: S105–115.
49. Thrane AS, Rappold PM, Fujita T, et al. Critical role of
aquaporin-4 (AQP4) in astrocytic Ca2þ signaling events eli-
cited by cerebral edema. Proc Natl Acad Sci U S A 2011; 108:
846–851.
50. Ito H, Yamamoto N, Arima H, et al. Interleukin-1beta induces
the expression of aquaporin-4 through a nuclear factor-
kappaB pathway in rat astrocytes. J Neurochem 2006; 99:
107–118.
51. Giles JA, Greenhalgh AD, Davies CL, et al. Requirement for
interleukin-1 to drive brain inflammation reveals tissue-
specific mechanisms of innate immunity. Eur J Immunol
2015; 45: 525–530.
52. Ohnishi M, Monda A, Takemoto R, et al. High-mobility
group box 1 up-regulates aquaporin 4 expression via
microglia-astrocyte interaction. Neurochem Int 2014; 75:
32–38.
53. Laird MD, Shields JS, Sukumari-Ramesh S, et al. High mobi-
lity group box protein-1 promotes cerebral edema after trau-
matic brain injury via activation of toll-like receptor 4. Glia
2014; 62: 26–38.
54. Rabolli V, Wallemme L, Lo Re S, et al. Critical role of
aquaporins in interleukin 1beta (il-1beta)-induced inflamma-
tion. J Biol Chem 2014; 289: 13937–13947.
55. Nakahama K, Nagano M, Fujioka A, et al. Effect of TPA on
aquaporin 4 mRNA expression in cultured rat astrocytes. Glia
1999; 25: 240–246.
Hirt et al. 7
